RayKnowChina Research Map
Shortlist

RecruitingLung cancerN/A

Registered title, quoted from ClinicalTrials.gov

Acupuncture Combined With PD-1/PD-L1 Inhibitors for Advanced Lung Cancer

An open trial on lung cancer, registered on ClinicalTrials.gov. Led by Guang'anmen Hospital; 1 other hospital on this site is listed as study site.

Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 2

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Lead sponsorGuang'anmen Hospital中国中医科学院广安门医院BeijingHospital page
  2. Study siteFirst Affiliated Hospital of Anhui Medical University安徽医科大学第一附属医院HefeiHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT06926140, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 7

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (7 points)Hide the checklist
  1. 18 years to 75 years; sex: all

    Registered eligibility fields

  2. Non-small cell lung cancer AJCC lung cancer staging of stage IIIB-IV, or small cell lung cancer staging of extensive stage;

    Inclusion criterion 3

  3. Those who have received acupuncture treatment or other clinical trials within 1 month prior to randomization;

    Exclusion criterion 9

  4. ECOG/PS score of grade 0-1 and expected survival ≥ 3 months;

    Inclusion criterion 2

  5. Non-small cell lung cancer adenocarcinoma patients do not have EGFR-sensitive mutations, ALK fusions, ROS1 fusions, BRAFV600 mutations, NTRK fusions, RET fusions, MET14 skipping mutations, and amplified gene-driven mutations by genetic testing;

    Inclusion criterion 5

  6. Having at least 1 measurable tumor lesion (diameter > 1cm) or lymph node short diameter ≥ 1.5cm;

    Inclusion criterion 9

  7. Those who are pregnant or breastfeeding;

    Exclusion criterion 6

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: diagnosis and how it was confirmed; other conditions the trial excludes.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT06926140, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion criteria:

  • Age 18-75 years;
  • ECOG/PS score of grade 0-1 and expected survival ≥ 3 months;
  • Non-small cell lung cancer AJCC lung cancer staging of stage IIIB-IV, or small cell lung cancer staging of extensive stage;
  • PD-L1 immunohistochemistry detection of tumor cell positive proportion score (TPS) <50%;
  • Non-small cell lung cancer adenocarcinoma patients do not have EGFR-sensitive mutations, ALK fusions, ROS1 fusions, BRAFV600 mutations, NTRK fusions, RET fusions, MET14 skipping mutations, and amplified gene-driven mutations by genetic testing;
  • Patients with no previous systemic therapy/first-line treatment;
  • Patients suitable for chemotherapy combined with immunotherapy;
  • Traditional Chinese Medicine (TCM) diagnosis of Qi Depression;
  • Having at least 1 measurable tumor lesion (diameter > 1cm) or lymph node short diameter ≥ 1.5cm;
  • Sign the informed consent form and voluntarily participate in this study.

Exclusion criteria:

  • Combined with other primary malignant tumors;
  • Those who have contraindications to immunotherapy after basic assessment of immunotherapy;
  • Those with autoimmune diseases or those who need long-term treatment with systemic steroids or immunosuppressants;
  • Those with combined serious and uncontrolled primary diseases of heart, cerebrovascular, liver, kidney, hematopoietic system and so on;
  • Those with metal allergy or severe fear of needles;
  • Those who are pregnant or breastfeeding;
  • Those who are unable to cooperate to complete the assessment due to mental disorder, intellectual or language impairment;
  • Those with active severe infectious or inflammatory diseases;
  • Those who have received acupuncture treatment or other clinical trials within 1 month prior to randomization;
  • In the judgment of the investigator, persons who have a concomitant medical condition that seriously jeopardizes the safety of the participant or interferes with the completion of the study, or who are deemed to have other reasons for not being suitable for enrollment.

Quoted from ClinicalTrials.gov, NCT06926140, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT06926140, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT06926140